bluuebunny/crossref_metadata_2025_split huggingface dataset:
Comprehensive analysis of intra-arterial treatment for acute ischemic stroke due to cervical artery dissection
Authors: Jensen Judd , Salottolo Kristin , Frei Donald , Loy David , McCarthy Kathryn , Wagner Jeffrey , Whaley Michelle , Bellon Richard , Bar-Or David 
Published: June 2016

ObjectiveThe safety and efficacy of intra-arterial treatment (IAT) in patients with acute ischemic stroke (AIS) due to cervical artery dissection (CeAD) has not been formally studied. The purpose of this study was twofold: first, describe a large series with CeAD treated with IAT; second, analyze outcomes with CeAD receiving IAT versus (a) CeAD not treated with IAT, (b) CeAD receiving intravenous thrombolysis (IVT) alone, and (c) non-CeAD mechanism of AIS receiving IAT.DesignDemographics, clinical characteristics, treatment, and outcomes were summarized for all CeAD patients treated with IAT from January 2010 to May 2015. Outcomes included favorable 90 day modified Rankin Scale (mRS) score of 0–2, symptomatic intracerebral hemorrhage (sICH), recanalization (Thrombolysis in Cerebral Infarction 2b-3), procedural complications, and mortality. Outcomes were analyzed with χ2tests and multivariate logistic regression.ResultsThere were 161 patients with CeAD: 24 were treated with IAT and comprised our target population. Dissections were more common in the internal carotid (n=18) than in the vertebral arteries (n=6). All but one patient had intracranial embolus. IAT techniques included thrombectomy (n=19), IA thrombolysis (n=17), stent (n=14), and angioplasty (n=7). Outcomes included favorable 90 day mRS score of 0–2 in 63%, 4 deaths, 1 sICH, and 3 procedural complications. After adjustment, favorable mRS in our target population was similar to comparison populations: (a) in CeAD, IAT versus no IAT (OR 0.62, p=0.56); (b) In CeAD, IAT versus IVT alone (OR 1.32, p=0.79); and (c) IAT in CeAD versus non-CeAD mechanism of AIS (OR 0.58, p=0.34).ConclusionsIAT is a valid alternative therapeutic option for AIS caused by CeAD due to the low complication rate and excellent outcomes observed in this study.
Two-year single-center experience with the ‘Baby Trevo’ stent retriever for mechanical thrombectomy in acute ischemic stroke
Authors: Kühn Anna Luisa , Wakhloo Ajay K , Lozano J Diego , Massari Francesco , De Macedo Rodrigues Katyucia , Marosfoi Miklos G , Perras Mary , Brooks Christopher , Howk Mary , Rex David E , Gounis Matthew J , Puri Ajit S 
Published: June 2016

ObjectiveTo evaluate the safety and efficacy of the ‘Baby Trevo’ (Trevo XP ProVue 3×20 mm Retriever) stent retriever for large vessel occlusions (LVOs) in acute ischemic stroke (AIS).Materials and methodsWe retrospectively analyzed our stroke database and included all patients treated with the Baby Trevo for distal LVOs in AIS. Patient gender, mean age, vascular risk factors, National Institutes of Health Stroke Scale (NIHSS) score at presentation, and modified Rankin Scale (mRS) score at baseline and 90-day follow-up were documented. Reperfusion rates for the vessels treated were recorded using the Thrombolysis in Cerebral Infarction (TICI) classification. Occurrence of vasospasm and new or evolving infarcts in the treated vascular territory was documented.ResultsThirty-five subjects with a mean NIHSS score of 18 were included. The Baby Trevo device was used in 38 branches of the anterior and posterior circulations. TICI 2b/3 blood flow was restored after one single pass in 20/38 (52.6%) and after two or three passes in 11 vessels. The remaining vessels required either more than three passes, showed less than a TICI 2b/3 reperfusion (n=3), or demonstrated failure to retrieve the clot (n=4). TICI 2b/3 reperfusion was achieved in 30 patients (85.7%). No vessel injuries, rupture, or significant vasospasm were seen. Overall, a mRS score of ≤2 was seen in 56.5% of the subjects successfully treated with the Baby Trevo at 90 days and in 81.3% of surviving patients; seven patients died (20%).ConclusionsOur preliminary data suggest that the ‘Baby Trevo’ achieves a high recanalization rate without any significant risk. Larger cohort studies are needed to validate the clinical benefit.
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Raje Noopur S. , Faber Edward A. , Richardson Paul G. , Schiller Gary , Hohl Raymond J. , Cohen Adam D. , Forero Andres , Carpenter Susan , Nguyen Tuan S. , Conti Ilaria , Kaiser Christopher J. , Cronier Damien M. , Wooldridge James E. , Anderson Kenneth C. 
Published: June 2016

AbstractPurpose: Tabalumab, a human mAb that neutralizes B-cell–activating factor (BAFF), demonstrated antitumor activity in xenograft models of multiple myeloma. Here we report on a phase I study of relapsed/refractory multiple myeloma patients in which the primary objective was to identify a tolerable and potentially efficacious dose of tabalumab when combined with bortezomib.Experimental Design: Forty-eight patients were enrolled; 20 to the dose-escalation cohort, and 28 to cohort expansion in which a dose of 100 mg of tabalumab was evaluated. All patients had received either prior bortezomib or an immunomodulatory drug; the median number of prior therapies was 3. Bortezomib was administered intravenously on days 1, 4, 8, and 11 of a 21-day schedule. Tabalumab was given every 21 days for 3 cycles, then every 42 days thereafter.Results: The most common grade 3/4 toxicities included thrombocytopenia, neutropenia, pneumonia, and peripheral sensory neuropathy. There were no dose-limiting toxicities, and the maximum tolerated dose was not reached. Pharmacokinetic data suggested serum exposure increased in a greater than dose-proportional manner up to a dose of 100 mg. Out of 46 evaluable patients, 20 had confirmed responses. The median time to progression (9 patients censored) was 4.8 months, and the median response duration (4 patients censored) was 7.2 months.Conclusions: A dose of 100 mg tabalumab in combination with bortezomib was well tolerated and active and is currently under further investigation. Clin Cancer Res; 22(23); 5688–95. ©2016 AACR.
Value of Image Fusion in Coronary Angiography for the Detection of Coronary Artery Bypass Grafts
Authors: Plessis Julien , Warin Fresse Karine , Cahouch Zachary , Manigold Thibaut , Letocart Vincent , Le Gloan Laurianne , Guyomarch Béatrice , Guerin Patrice 
Published: June 2016

Background

Coronary angiography is more complex in patients with coronary artery bypass grafts (
CABG
). Image fusion is a new technology that allows the overlay of a computed tomography (
CT
) three‐dimension (3D) model with fluoroscopic images in real time.

Methods and Results

This single‐center prospective study included 66 previous
CABG
patients undergoing coronary and bypass graft angiography. Image fusion coronary angiographies (fusion group, 20 patients) were compared to conventional coronary angiographies (control group, 46 patients). The fusion group included patients for whom a previous chest
CT
scan with contrast was available. For patients in this group, aorta and
CABG
were reconstructed in 3D from
CT
acquisitions and merged in real time with fluoroscopic images. The following parameters were compared: time needed to localize the
CABG
; procedure duration; air kerma (
AK
); dose area product (
DAP
); and volume of contrast media injected. Results are expressed as median. There were no significant differences between the 2 groups in patient demographics and procedure characteristics (access site, number of bypass to be found, and interventional cardiologist's experience). The time to localize
CABG
was significantly shorter in the fusion group (7.3 versus 12.4 minutes;
P
=0.002), as well as the procedure duration (20.6 versus 25.6 minutes;
P=
0.002),
AK
(610 versus 814 mGy;
P=
0.02),
DAP
(4390 versus 5922.5 cGy·cm
2
;
P
=0.02), and volume of iodinated contrast media (85 versus 116 cc;
P
=0.002).

Conclusions

3D image fusion improves the
CABG
detection in coronary angiography and reduces the time necessary to localize
CABG
, total procedure time duration, radiation exposure, and volume of contrast media.
The relationship between childhood trauma and type D personality in university students
Authors: Demirci Kadir , Yıldız Mesut , Selvi Cansu , Akpınar Abdullah 
Published: June 2016

Aim: There has been increasing evidence that childhood traumas are related to reduced health-related quality of life, neurobiological changes and long-term adverse effects, such as an increase in the likelihood of psychiatric disorders in adulthoods. The aim of this study was to investigate the relationships between childhood traumas and type D personality. Subjects and methods: In total, 187 university students (64 males and 123 females; mean age = 21.69 ± 2.00) were included in the study. All participants were evaluated using the Type D Personality Scale (DS-14), Childhood Trauma Questionnaire (CTQ-28) and Beck Depression Inventory (BDI). The participants were divided into the two groups according to the presence of type D personality. Then, statistical analyses were performed. Results: The frequency of type D personality in participants was 43.3% ( n = 81). The emotional neglect, physical neglect, emotional abuse component of the CTQ-28, total CTQ-28 scores and BDI scores were higher in the group with type D personality than in the group without type D personality ( p < .001, p = .003, p = .001, p < .001 and p < .001, respectively). There were significantly positive correlations between the type D personality scores and BDI scores, emotional neglect, physical neglect, emotional abuse and childhood trauma total scores ( p < .05, for all). Linear regression analyses showed that the significant and independent predictors of the score of DS-14 were total score of CTQ-28 and BDI score. Conclusion: Childhood trauma may be associated with type D personality, and there is predictive value of the childhood trauma on the scores of type D personality.
Tricuspid valve repair for severe tricuspid regurgitation due to pacemaker leads
Authors: Uehara Kyokun , Minakata Kenji , Watanabe Kentaro , Sakaguchi Hisashi , Yamazaki Kazuhiro , Ikeda Tadashi , Sakata Ryuzo 
Published: June 2016

Background Tricuspid valve regurgitation due to pacemaker leads is a well-known complication. Although some reports have suggested that pacemaker leads should be surgically explanted, strongly adhered leads cannot always be removed. The aim of this study was to describe our tricuspid valve repair techniques with pacemaker leads left in situ. Methods Our retrospective study investigated 6 consecutive patients who required tricuspid valve surgery for severe regurgitation induced by pacemaker leads. Results From the operative findings, we identified 3 patterns of tricuspid valve and pacemaker lead involvement. In 3 patients, the leads were caught in the chordae, in 2 patients, tricuspid regurgitation was caused by lead impingement on the septal leaflet, and in 3 patients, tricuspid valve leaflets had been perforated by the pacemaker leads. During surgery, all leads were left in situ after being separated from the leaflet or valvular apparatus. In addition, suture annuloplasty was performed for annular dilatation in all cases. In one patient, the lead was reaffixed to the annulus after the posterior leaflet was cut back towards the annulus, and the leaflet was then closed. There was one hospital death due to sepsis. The degree of tricuspid regurgitation was trivial in all surviving patients at discharge. During a mean follow-up of 21 months, one patient died from pneumonia 20 months after tricuspid valve repair. Conclusion In patients undergoing tricuspid valve surgery due to severe tricuspid regurgitation caused by pacemaker leads, the leads can be left in situ after proper repair with annuloplasty.
Effect on Clinical Outcome and Growth Factor Synthesis With Adjunctive Use of Pulsed Electromagnetic Fields for Fifth Metatarsal Nonunion Fracture
Authors: Streit Adam , Watson B. Collier , Granata Jaymes D. , Philbin Terrence M. , Lin Hsuan-Ni , O’Connor J. Patrick , Lin Sheldon 
Published: June 2016

Background: Electromagnetic bone growth stimulators have been found to biologically enhance the bone healing environment, with upregulation of numerous growth factors. The purpose of the study was to quantify the effect, in vivo, of pulsed electromagnetic fields (PEMFs) on growth factor expression and healing time in fifth metatarsal nonunions. Methods: This was a prospective, randomized, double-blind trial of patients, cared for by 2 fellowship-trained orthopedic foot and ankle surgeons. Inclusion criteria consisted of patients between 18 and 75 years old who had been diagnosed with a fifth metatarsal delayed or nonunion, with no progressive signs of healing for a minimum of 3 months. Eight patients met inclusion criteria and were randomized to receive either an active stimulation or placebo PEMF device. Each patient then underwent an open biopsy of the fracture site and was fitted with the appropriate PEMF device. The biopsy was analyzed for messenger-ribonucleic acid (mRNA) levels using quantitative competitive reverse transcription polymerase chain reaction (QT-RT-PCR). Three weeks later, the patient underwent repeat biopsy and open reduction and internal fixation of the nonunion site. The patients were followed at 2- to 4-week intervals with serial radiographs and were graded by the number of cortices of healing. Results: All fractures healed, with an average time to complete radiographic union of 14.7 weeks and 8.9 weeks for the inactive and active PEMF groups, respectively. A significant increase in placental growth factor (PIGF) level was found after active PEMF treatment ( P = .043). Other factors trended higher following active PEMF including brain-derived neurotrophic factor (BDNF), bone morphogenetic protein (BMP) -7, and BMP-5. Conclusion: The adjunctive use of PEMF for fifth metatarsal fracture nonunions produced a significant increase in local placental growth factor. PEMF also produced trends toward higher levels of multiple other factors and faster average time to radiographic union compared to unstimulated controls. Level of Evidence: Level I, prospective randomized trial.
Urology higher specialist training in North London and North West England: a comparison of two training regions in the UK
Authors: Babu Asrit , Alleemudder Adam , Kavia Rajesh , Datta Sam , Maan Zafar 
Published: June 2016

Introduction: Local education training boards (LETBs) and deaneries are under pressure to demonstrate delivery of high quality specialist urology training. There is at present no quality tool used routinely to demonstrate this quality regionally or nationally. Differences in training could therefore exist between different regions, and locally between different training units. A trainer/trainee questionnaire tool previously piloted by the specialist advisory committee was used to evaluate urology training posts in the North London LETB over 3 years. The findings were used to compare trainee scores in North London with those in the North West region of England. Materials and methods: Questionnaires were circulated electronically to all higher surgical urology trainees in the 18 training units affiliated to the North London LETB. Three years of trainee data were collated, statistically analysed and compared to those collected by Oates and colleagues, looking for any differences in regional trainee scores for higher surgical training posts in North London and North West of England regions. Results: The mean trainee response rate was 28 questionnaires per year from all 18 units in the North London region. Combined mean and median scores were 83.3 and 84, respectively. This compares to 86.2 and 88.1 from North West England region comprising eight units. There was no statistically significant difference in scores between the two regions (two-tailed t test, P=0.31). Conclusion: There is no statistical difference in trainee scores for the evaluation of urological training posts between the two regions. The questionnaire tool can be used effectively to look at overall differences in training standards between geographically distinct regions from a trainee perspective. Both regions offer higher surgical training with high levels of trainee satisfaction. This questionnaire tool can provide insight into subjective differences in training posts within a region.
mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation
Authors: Yang Jun , Zhou Xuan , Fan Xiaorong , Xiao Min , Yang Dinghua , Liang Bo , Dai Meng , Shan Lanlan , Lu Jingbo , Lin Zhiqi , Liu Rong , Liu Jun , Wang Liping , Zhong Mei , Jiang Yu , Bai Xiaochun 
Published: June 2016

Key Points
Activation of mTORC1 in MKs and platelets contributes to aging-related venous thrombosis. ROS production with aging activates mTORC1 to elevate MPV and platelet activation and promote venous thrombosis.
IRF2BP2 transcriptional repressor restrains naive CD4 T cell activation and clonal expansion induced by TCR triggering
Authors: Sécca Cristiane , Faget Douglas V , Hanschke Steffi C , Carneiro Mayra S , Bonamino Martin H , de-Araujo-Souza Patricia S , Viola João P B 
Published: June 2016

Abstract
CD4 T cell activation and differentiation mechanisms constitute a complex and intricate signaling network involving several regulatory proteins. IRF2BP2 is a transcriptional repressor that is involved in gene-expression regulation in very diverse biologic contexts. Information regarding the IRF2BP2 regulatory function in CD4 T lymphocytes is very limited and suggests a role for this protein in repressing the expression of different cytokine genes. Here, we showed that Irf2bp2 gene expression was decreased in CD4 T cells upon activation. To investigate the possible regulatory roles for IRF2BP2 in CD4 T cell functions, this protein was ectopically expressed in murine primary-activated CD4 T lymphocytes through retroviral transduction. Interestingly, ectopic expression of IRF2BP2 led to a reduction in CD25 expression and STAT5 phosphorylation, along with an impaired proliferative capacity. The CD69 expression was also diminished in IRF2BP2-overexpressing cells, whereas CD44 and CD62L levels were not altered. In vivo, transferred, IRF2BP2-overexpressing, transduced cells displayed an impaired expansion capacity compared with controls. Furthermore, overexpression of IRF2BP2 in differentiated Th cells resulted in slightly reduced IL-4 and pro-TGF-β production in Th2 and iTregs but had no effect on IFN-γ or IL-17 expression in Th1 and Th17 cells, respectively. Taken together, our data suggest a role for IRF2BP2 in regulating CD4 T cell activation by repressing proliferation and the expression of CD25 and CD69 induced by TCR stimuli.
Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors
Authors: Frick Kevin D. , Snyder Claire F. , Herbert Robert J. , Blackford Amanda L. , Neville Bridget A. , Wolff Antonio C. , Carducci Michael A. , Earle Craig C. 
Published: June 2016

Purpose: To estimate the association between cancer survivors’ comorbid condition care quality and costs; to determine whether the association differs between cancer survivors and other patients. Methods: Using the SEER–Medicare-linked database, we identified survivors of breast, prostate, and colorectal cancers who were diagnosed in 2004, enrolled in Medicare fee-for-service for at least 12 months before diagnosis, and survived ≥ 3 years. Quality of care was assessed using nine process indicators for chronic conditions, and a composite indicator representing seven avoidable outcomes. Total costs on the basis of Medicare amount paid were grouped as inpatient and outpatient. We examined the association between care quality and costs for cancer survivors, and compared this association among 2:1 frequency-matched noncancer controls, using comparisons of means and generalized linear regressions. Results: Our sample included 8,661 cancer survivors and 17,332 matched noncancer controls. Receipt of recommended care was associated with higher outpatient costs for eight indicators, and higher inpatient and total costs for five indicators. For three measures (visit every 6 months for patients with chronic obstructive pulmonary disease or diabetes, and glycosylated hemoglobin or fructosamine every 6 months for patients with diabetes), costs for cancer survivors who received recommended care increased less than for noncancer controls. The absence of avoidable events was associated with lower costs of each type. An annual eye examination for patients with diabetes was associated with lower inpatient costs. Conclusion: Higher-quality processes of care may not reduce short-term costs, but the prevention of avoidable outcomes reduces costs. The association between quality and cost was similar for cancer survivors and noncancer controls.
Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment
Authors: Freedman Rachel A. , Kouri Elena M. , West Dee W. , Lii Joyce , Keating Nancy L. 
Published: June 2016

Purpose:Knowledge about one’s breast cancer characteristics is poor, but whether this knowledge affects treatment is uncertain. Among women with breast cancer, we examined whether tumor knowledge was associated with adjuvant treatment receipt.Methods:We surveyed a population-based sample of women in Northern California with stage 0 to III breast cancer diagnosed during 2010 to 2011 (participation rate, 68.5%). Interviews were conducted between 4 months and 3 years after diagnosis. Among 414 respondents with stage I to III disease, we examined receipt of guideline-recommended chemotherapy, radiation, and hormonal therapy by reporting correct information about one’s tumor, including stage, estrogen receptor, human epidermal growth factor receptor 2 (HER2), and grade (using registry data for confirmation). We performed multivariate logistic regression to assess the probability of receiving each treatment in relevant patient groups, adjusting for patient and tumor characteristics, and examined the impact of reporting correct tumor information on treatment receipt.Results:Among relevant treatment-eligible groups, 81% received chemotherapy, 91% received radiation, and 83% received hormonal therapy. In adjusted analyses, having correct (v incorrect) information for stage and HER2 were associated with chemotherapy receipt (odds ratio [OR], 4.45; 95% CI, 1.50 to 12.50 for stage; OR, 2.70; 95% CI, 1.02 to 7.18 for HER2). Correctly reporting estrogen receptor status was associated with hormonal therapy receipt (OR, 3.91; 95% CI, 1.73 to 8.86), and correctly reporting stage was associated with radiation receipt (OR, 2.76; 95% CI, 1.03 to 7.40).Conclusion:Knowledge about one’s tumor characteristics was strongly associated with receipt of recommended therapies. Interventions to improve patients’ knowledge and understanding of their cancers should be tested as a strategy for improving receipt of care.